Q-omics provides the consensus-scored NDUFA12 profile across patient tissues and cancer cell-line models. NDUFA12 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NDUFA12 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, NDUFA12 protein abundance shows 19,008 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where NDUFA12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NDUFA12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NDUFA12 survival associations across molecular data types. NDUFA12 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NDUFA12 RNA expression–survival associations across cancer types. High NDUFA12 expression shows unfavorable associations in UVM, HNSC, LUAD, LIHC, MESO and ACC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NDUFA12 RNA expression.
This table summarizes NDUFA12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NDUFA12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NDUFA12 shows higher tumor expression in HNSC, KIRC, LIHC, KIRP, LUSC and UCEC. The HNSC box plot shows higher NDUFA12 RNA expression in tumor versus normal tissue (log2 FC = +0.493, t-test p < 0.001).
This table shows molecular features associated with NDUFA12 in patient tissues and cancer cell lines. In patient samples, NDUFA12 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NDUFA12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Lymphoma.
